Overview

Sacubitril 97 mg and Valsartan 103 mg Film-coated Tablets Relative to Entresto 97 mg/103 mg Film-coated Tablets

Status:
NOT_YET_RECRUITING

Trial end date:
2024-07-06

Target enrollment:

Participant gender:

Summary

The study is to compare the rate and extent of absorption of a generic formulation with that of a reference for mulation when given as equal labeled dose. The study will be a randomized, open-label, single oral dose, full replicated crossover design with four-period, two-treatment, and two-sequence under fasting condition and at least 14 days washout period between the doses.

Phase:

PHASE1

Details

Lead Sponsor:

Bio-innova Co., Ltd

Treatments:

sacubitril